V souladu s legislativou České republiky poskytuje Společnost služby pouze kvalifikovaným investorům!

Verve Therapeutics (VERV) Financial results for the second quarter of 2021.

12.08.2021

GAAP net loss is -$6.66, that is $3.25 worse than the same period last year.

Cash and cash equivalents are $417.6 million as of June 30, 2021.